Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.50
Ask: 38.75
Change: -0.575 (-1.47%)
Spread: 0.25 (0.649%)
Open: 39.05
High: 39.20
Low: 39.00
Prev. Close: 39.20
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Manufacturing and Distribution Agreements with TTK

13 Jun 2016 07:00

RNS Number : 9244A
Futura Medical PLC
13 June 2016
 

For immediate release

13 June 2016

 

 

Futura Medical plc

("Futura" or the "Company")

 

Signs Manufacturing and Distribution Agreements with TTK

 

 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that it has signed manufacturing and distribution agreements with TTK Protective Devices Limited ("TTK"), a pioneer in the condom business and part of the substantial Indian conglomerate TTK Group.

 

Under the terms of the manufacturing agreement, TTK will manufacture CSD500, Futura's novel erectogenic condom for supply worldwide. A regulatory filing has already been made with EU regulatory authorities to grant TTK the relevant authorisation to manufacture the product.

 

TTK will be one of two manufacturers of CSD500 as part of the Company's strategy to guarantee international supply. A European manufacturer already holds regulatory authorisation to manufacture the version of CSD500 currently marketed in the Netherlands and is awaiting regulatory authorisation for the extended shelf-life version of the product.

 

Futura has also signed an exclusive licensing agreement with TTK for the marketing and distribution of CSD500 in India for the lifetime of the patents. Futura will receive an upfront payment and royalties on product sales over the duration of the agreement.

 

TTK already owns the fastest growing condom brand in India, SKORE, which since its launch three years ago has achieved in excess of a 10% market share. TTK is attracted by the unique characteristics of CSD500 to further drive the growth of the SKORE brand. Subject to regulatory approval, CSD500 is expected to be launched by TTK in Q1 2017.

 

James Barder, Futura Medical's Chief Executive, said: "I am delighted to sign these two agreements for worldwide manufacturing and for distribution in India of our novel erectogenic condom, CSD500. It has always been our manufacturing strategy to offer CSD500's licensees the guarantee of supply by having dual sourced manufacture in Europe and in Asia. TTK is an ideal manufacturing partner as it is a highly experienced condom maker that has supplied the world's largest condom brands.

 

"I am also delighted to sign an exclusive agreement with TTK for the marketing and distribution of CSD500 in India. TTK's SKORE brand is the fastest growing condom brand in India and we look forward to CSD500 becoming a further growth driver in the SKORE franchise."

 

Mr T T Raghunathan, TTK Protective Device's Managing Director, said: "We are very pleased to be working with Futura Medical both in manufacturing CSD500 for worldwide supply and in distributing the product in India. TTK has always stood for innovation and quality in the global condom market, in which we have a long track record in manufacturing high quality condoms. We also look forward to the success of combining India's fastest growing condom brand, SKORE, with the innovation that CSD500 brings to condom users."

 

 

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

Email to: james.barder@futuramedical.com

www.futuramedical.com

 

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Liz YongCorporate Finance

 

Tel:+44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan

Mark Court / Sophie Cowles / Stephanie Watson

Tel: +44 (0) 20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRGGURUQUPQGQU
Date   Source Headline
26th Nov 20186:00 pmRNSApplication for Block Listing
19th Nov 20183:43 pmRNSHolding(s) in Company
19th Nov 20182:29 pmRNSHolding(s) in Company
19th Nov 20182:24 pmRNSHolding(s) in Company
19th Nov 201811:03 amRNSDirectors' / PDMR Dealing and Grant of Options
15th Nov 201811:36 amRNSHolding(s) in Company
13th Nov 20187:00 amRNSDirector/PDMR Dealings
12th Nov 20182:17 pmRNSResult: Open Offer General Meeting & Voting Rights
9th Nov 20187:00 amRNSPresents Data on MED2005 at SMSNA Annual Meeting
6th Nov 20188:29 amRNSHolding(s) in Company
31st Oct 20187:00 amRNS1st Patient Enrolled in European Ph3 MED2002 study
24th Oct 201810:19 amRNSPosting of Circular and Notice of General Meeting
19th Oct 20189:05 amRNSSecond Price Monitoring Extn
19th Oct 20189:00 amRNSPrice Monitoring Extension
19th Oct 20187:00 amRNSFurther Details on the Fundraising
18th Oct 20185:16 pmRNSOffer on PrimaryBid.com
18th Oct 20185:04 pmRNSProposed Fundraising
1st Oct 20187:00 amRNSHolding(s) in Company
26th Sep 20187:00 amRNSInterim Results for the Six Months 30 June 2018
24th Sep 20183:39 pmRNSTR-1: Notification of major holdings
24th Sep 20187:00 amRNSHolding(s) in Company
24th Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20184:41 pmRNSSecond Price Monitoring Extn
20th Sep 20184:35 pmRNSPrice Monitoring Extension
19th Sep 20189:05 amRNSSecond Price Monitoring Extn
19th Sep 20189:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSBusiness Update
29th Aug 20187:00 amRNSNotice of Interim Results
23rd Jul 20187:00 amRNSTPR 100: UK Regulatory Submission
13th Jun 20186:22 pmRNSResult of AGM
13th Jun 20187:00 amRNSAGM Statement
31st May 20186:20 pmRNSTotal Voting Rights
30th May 201810:20 amRNSBlock Listing Interim Review
25th May 20187:00 amRNSApplication for Block Listing
27th Apr 20185:11 pmRNSNotification of Major Interest in Shares
26th Apr 20187:00 amRNSPhase III efficacy study of MED2002
25th Apr 20187:00 amRNSPositive data from MED2002 PK study
6th Apr 201812:13 pmRNSNotice of AGM
14th Mar 20187:00 amRNSPreliminary Results
13th Mar 20187:00 amRNSPositive Interim Data from MED2002 PK study
20th Feb 20187:00 amRNSDirectorate Changes
15th Feb 20187:00 amRNSNotification of Preliminary Results
31st Jan 201810:39 amRNSTotal Voting Rights
4th Jan 20187:00 amRNSPublication of Positive MED2002 Clinical Data
3rd Jan 20183:08 pmRNSDirector/PDMR Shareholding
2nd Jan 20183:50 pmRNSRemuneration of Non-Executive Directors and TVR
29th Nov 20177:00 amRNSMED2002: Regulatory, Clinical & Commercial Update
29th Nov 20177:00 amRNSMED2002: PK Study Commences
24th Nov 20171:08 pmRNSBlock Listing Update
23rd Oct 20173:30 pmRNSPDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.